Alex Chia Yu Chang

Dr. Alex Chia Yu Chang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PBPaul W Burridge
Paul W Burridge
YLYong Fuga Li
Yong Fuga Li
EMElena Matsa
Elena Matsa
HWHaodi Wu
Haodi Wu
SOSang-Ging Ong
Sang-Ging Ong
JWJoseph C Wu
Joseph C Wu

16 November 2012 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
VGVictoria C. Garside
Victoria C. Garside
ACAlex Chia Yu Chang
Alex Chia Yu Chang
AKAly Karsan
Aly Karsan
PHPamela A. Hoodless
Pamela A. Hoodless

1 August 2011 in Developmental Cell
Verified
Journal Article
Closed access
ACAlex Chia Yu Chang
Alex Chia Yu Chang
YFYangXin Fu
YangXin Fu
VGVictoria C. Garside
Victoria C. Garside
KNKyle Niessen
Kyle Niessen
LCLinda Chang
Linda Chang
AKAly Karsan
Aly Karsan

16 February 2018 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
NYNora Yucel
Nora Yucel
ACAlex Chia Yu Chang
Alex Chia Yu Chang
JDJohn W. Day
John W. Day
NRNadia A. Rosenthal
Nadia A. Rosenthal
HBHelen M. Blau
Helen M. Blau
Duchenne muscular dystrophy (DMD) is a common fatal heritable myopathy, with cardiorespiratory failure occurring by the third decade of life. There is no specific treatment for DMD cardiomyopathy, in large part due to a lack of understanding of the mechanisms underlying the cardiac failure. Mdx mice, which have the same dystrophin mutation as human patients, are of limited use, as they do not develop early dilated cardiomyopathy as seen in patients. Here we summarize the usefulness of the various commonly used DMD mouse models, highlight a model with shortened telomeres like humans, and identify directions that warrant further investigation.

20 June 2019 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
HWHaodi Wu
Haodi Wu
HYHuaxiao Yang
Huaxiao Yang
JRJune-Wha Rhee
June-Wha Rhee
JZJoe Z Zhang
Joe Z Zhang
Chi Keung LamChi Keung Lam
Chi Keung Lam
JWJoseph C Wu
Joseph C Wu
Diastolic dysfunction (DD) is common among hypertrophic cardiomyopathy (HCM) patients, causing major morbidity and mortality. However, its cellular mechanisms are not fully understood, and presently there is no effective treatment. Patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) hold great potential for investigating the mechanisms underlying DD in HCM and as a platform for drug discovery. In the present study, beating iPSC-CMs were generated from healthy controls and HCM patients with DD. Micropatterned iPSC-CMs from HCM patients showed impaired diastolic function, as evidenced by prolonged relaxation time, decreased relaxation rate, and shortened diastolic sarcomere length. Ratiometric Ca2+ imaging indicated elevated diastolic [Ca2+]i and abnormal Ca2+ handling in HCM iPSC-CMs, which were exacerbated by β-adrenergic challenge. Combining Ca2+ imaging and traction force microscopy, we observed enhanced myofilament Ca2+ sensitivity (measured as dF/Δ[Ca2+]i) in HCM iPSC-CMs. These results were confirmed with genome-edited isogenic iPSC lines that carry HCM mutations, indicating that cytosolic diastolic Ca2+ overload, slowed [Ca2+]i recycling, and increased myofilament Ca2+ sensitivity, collectively impairing the relaxation of HCM iPSC-CMs. Treatment with partial blockade of Ca2+ or late Na+ current reset diastolic Ca2+ homeostasis, restored diastolic function, and improved long-term survival, suggesting that disturbed Ca2+ signalling is an important cellular pathological mechanism of DD. Further investigation showed increased expression of L-type Ca2+channel (LTCC) and transient receptor potential cation channels (TRPC) in HCM iPSC-CMs compared with control iPSC-CMs, which likely contributed to diastolic [Ca2+]i overload. In summary, this study recapitulated DD in HCM at the single-cell level, and revealed novel cellular mechanisms and potential therapeutic targets of DD using iPSC-CMs.

1 May 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
JZJoe Z. Zhang
Joe Z. Zhang
VTVittavat Termglinchan
Vittavat Termglinchan
NSNing-Yi Shao
Ning-Yi Shao
IIIlanit Itzhaki
Ilanit Itzhaki
CLChun Liu
Chun Liu
JWJoseph C. Wu
Joseph C. Wu